VAUDREUIL-DORION, QUEBEC–(Marketwired – Jan 26, 2017) – Immunotec Inc. (TSX VENTURE:IMM), a direct-to- consumer company and leader in the nutritional industry (the “Company” or “Immunotec”), today announced its fourth quarter financial results for Fiscal 2016. All amounts in this press release are in Canadian dollars unless otherwise indicated.
“Annual revenues surpassed our expectations and reached an all-time high of $109 million, reflecting solid performances in all regions by Immunotec’s Consultants and Employees. The weakness of the Mexican Peso significantly impacted profitability during the fourth quarter. On a currency neutral basis, we estimate that this volatility reduced the Adjusted EBITDA1 by approximately $3.4 million compared to last year”, said Charles Orr, Chief Executive Officer.
QUARTERLY PERFORMANCE HIGHLIGHTS
- Network sales amounted to $29.7M, an increase of 30.7% over last year, while sponsoring1 of new customers and consultants increased by 50.9% over last year.
- Network sales in key geographies grew by 58.4% in Mexico, 15.9% in the United States and 6.7% in Canada.
- Margin before expenses were down by 2.4%, to 73.0%, and Adjusted EBITDA1 amounted to 2.9% of revenues, considering the impact from the recent foreign currency devaluation of the Mexican Peso.
- Net profit totalled $0.6M or $0.01 basic and fully diluted profit per common share.
“For the year, we are very pleased by the overall performance of our Network Sales and Sponsoring activities, representing a significant recovery over the prior year which was negatively impacted by the implementation of a 16% value-added tax in Mexico”, said Patrick Montpetit, Chief Financial Officer of Immunotec. “Management’s disciplined approach to corporate expenses led to a significant decline of these expenses as a percentage of total revenues. Finally, our balance sheet improved substantially with year-end cash of $13.9 million, reflecting solid cash flows from operations.”
“Among efforts to contain the impact of the weak Mexican Peso, we have implemented price increases of 5 to 7% in all our markets effective on January 1st, 2017. This combined with other management initiatives should mitigate a significate portion of the foreign exchange impact on profitability. As we enter Fiscal 2017, we are confident in our ability to maintain the momentum of the past year and continue to better leverage the scale of our Company. Furthermore, the Company is pleased to announce that Charles Orr’s employment agreement has been renewed until June 30, 2017″, concluded Mr. Montpetit.
Results of operations | |||||||
For the periods ended October 31, | Three-months | Twelve-months | |||||
(‘000s of C$, except for share and per share data) | 2016 | 2015 | 2016 | 2015 | |||
Revenues | 32,113 | 24,804 | 109,013 | 84,758 | |||
Cost of sales | 8,674 | 6,113 | 28,200 | 20,350 | |||
Margin before expenses | 23,439 | 18,691 | 80,813 | 64,408 | |||
Expenses | 22,708 | 16,819 | 77,009 | 59,194 | |||
Operating income | 731 | 1,872 | 3,804 | 5,214 | |||
Net finance (income) expenses | (505 | ) | (58 | ) | 179 | 137 | |
Income taxes | 650 | 215 | 1,510 | 1,035 | |||
Net profit | 586 | 1,715 | 2,115 | 4,042 | |||
Total comprehensive income | 663 | 1,626 | 1,934 | 4,006 | |||
Total basic and diluted net profitper common share | 0.01 | 0.02 | 0.03 | 0.06 | |||
Weighted average number ofcommon shares oustandingduring the year | |||||||
Basic | 69,761,628 | 69,287,627 | 69,639,953 | 69,152,836 | |||
Diluted | 70,083,720 | 69,290,915 | 69,886,364 | 69,156,574 | |||
Revenues and sponsoring 1 | |||||||||
For the periods ended October 31, | Three-months | Twelve-months | |||||||
(‘000s of C$) | 2016 | 2015 | Variation | 2016 | 2015 | Variation | |||
Network sales | 29,671 | 22,707 | 30.7 | % | 100,602 | 77,320 | 30.1 | % | |
Other revenue | 2,442 | 2,097 | 16.4 | % | 8,411 | 7,438 | 13.1 | % | |
32,113 | 24,804 | 29.5 | % | 109,013 | 84,758 | 28.6 | % | ||
Network sales in key markets in local currency | 2016 | 2015 | Variation | 2016 | 2015 | Variation | |||
Mexico (‘000s of Mexican pesos) | 241,970 | 152,738 | 58.4 | % | 736,584 | 503,666 | 46.2 | % | |
United States (‘000s of US$) | 6,695 | 5,778 | 15.9 | % | 24,567 | 20,049 | 22.5 | % | |
Canada (‘000s of C$) | 3,134 | 2,936 | 6.7 | % | 12,022 | 11,312 | 6.3 | % | |
Sponsoring1of new customers and consultants in key markets (# of people) | 2016 | 2015 | Variation | 2016 | 2015 | Variation | |||
Mexico | 30,001 | 17,432 | 72.1 | % | 83,923 | 55,515 | 51.2 | % | |
United States | 6,158 | 6,137 | 0.3 | % | 22,844 | 18,747 | 21.9 | % | |
Canada | 1,967 | 1,691 | 16.3 | % | 8,140 | 6,291 | 29.4 | % | |
38,126 | 25,260 | 50.9 | % | 114,907 | 80,553 | 42.6 | % |
Calculation of adjusted EBITDA1 | |||||||||
For the periods ended October 31, | Three-months | Twelve-months | |||||||
(‘000s of C$) | 2016 | 2015 | 2016 | 2015 | |||||
Net profit | 586 | 1,715 | 2,115 | 4,042 | |||||
Add: | |||||||||
Depreciation and amortization | 169 | 177 | 680 | 668 | |||||
Net finance (income) expenses | (505 | ) | (58 | ) | 179 | 137 | |||
Other expenses | 45 | 30 | 1,046 | 197 | |||||
Income taxes | 650 | 215 | 1,510 | 1,035 | |||||
Adjusted EBITDA | 945 | 2,079 | 5,530 | 6,079 | |||||
as a % of Revenues | 2.9 | % | 8.4 | % | 5.1 | % | 7.2 | % |
Be the first to comment on "Immunotec Reports Fourth Quarter and Full-Year 2016 Results"